

## Special Issue

# Advances in Cancer Immunology and Immunotherapy

### Message from the Guest Editors

Discuss recent discoveries in tumor immunology as well as immunotherapy and the insights of those discoveries for further therapies. You are welcome to contribute a novel report, observation, or review article that focuses on (i) recent discoveries in tumor immunology and immunotherapy, (ii) a mechanistic explanation of the limitations of current tumor studies and immunotherapy, (iii) how to translate current knowledge into further therapies, (iv) future directions of tumor immunology studies, and (v) novel techniques as well as models which can help future tumor immunology studies. Update the community on the latest progress in tumor immunology as well as immunotherapy and point out future directions for researchers. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: tumor immunology, immunotherapy, and novel tumor models. We look forward to receiving your contributions.

### Guest Editors

Dr. Wenjie Jin

Institute for Translational Bioengineering, F. Hoffmann-La Roche  
Grenzacherstrasse 124, 4070 Basel, Switzerland

Dr. Zihe Huo

Department Biomedizin, University of Basel, DBM Hebelstrasse - FG  
Guzman, Hebelstrasse 20, 4031 Basel, Switzerland

### Deadline for manuscript submissions

closed (1 February 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/164579](https://mdpi.com/si/164579)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[vaccines](https://vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).